ChemoCentryx reported increased R&D and administrative expenses leading to a higher net loss, which may weigh on investor sentiment in the short term. However, the advancement of multiple clinical trials and a strong cash position provide some positive outlook. Overall, the immediate impact is likely to be slightly negative.

[-1]